TheraP: a randomized phase 2 trial of ¹⁷⁷ Lu‐ <scp>PSMA</scp> ‐617 theranostic treatment vs cabazitaxel in progressive metastatic castration‐resistant prostate cancer (Clinical Trial Protocol <scp>ANZUP</scp> 1603)

Abstract

¹⁷⁷ Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC. The results of this trial will determine, for the first time in a randomized design, the activity and safety of ¹⁷⁷ Lu-PSMA-617, as compared with cabazitaxel chemotherapy in men with progressive mCRPC.